NTHI
NeOnc Technologies Holdings, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
NeOnc Technologies (NTHI) Stock: Buy, Sell, or Hold?
$4.52
+0.15 (+3.43%)
▲
5d:
+42.59%
30d:
+74.18%
90d:
+40.81%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 13, 2026
TODAY
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (21%)
Quality Score
37/100
Position
EXTENDED
30-Day Fair Range
$2.60 – $3.53
Position: EXTENDED
Forward P/E & Valuation
-4.2x
Next 12M consensus est.
Wall Street Target
$17.00
+276.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$2.91 / $4.80
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR BETTER ENTRY: NTHI is 28.0% above its trading range ($3.53). While momentum could continue, risk/reward favors waiting for a pullback.
Get Alerted When NTHI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: NTHI is currently trading at $4.52, which is considered extended relative to its 30-day fair value range of $2.60 to $3.53.
Technical Outlook: Technically, NTHI is in a downtrend. Immediate support is located at $2.91, while resistance sits at $4.80. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: NTHI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.00 (+276.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NTHI is in a downtrend. Immediate support is located at $2.91, while resistance sits at $4.80. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: NTHI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.00 (+276.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.60 -
$3.53
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
Trading Range & Key Levels
30-Day Trading Range
$2.60 -
$3.53
Current vs Trading Range
EXTENDED
Support Level
$2.91
Resistance Level
$4.80
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- BEARISH: Price significantly overextended (+28.0% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BULLISH: Trading 276.1% below Wall St target ($17.00)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-4.15
Wall Street Target
$17.00
(+276.1%)
Revenue Growth (YoY)
-100.0%
Share NTHI Analysis
Share this live NTHI analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (NTHI)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary:
NeOnc Technologies received a Type B End-of-Phase meeting with the FDA to discuss potential accelerated approval and design of Phase 3 trial for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma.
Key Retail Themes:
FDA meeting
Accelerated approval
Phase 3 trial design
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:00 PM ET
Data refreshes hourly during market hours. Next update: 9:00 PM
Data refreshes hourly during market hours. Next update: 9:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NTHI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 33 SELL |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 43 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive NTHI Research Pages